2026. The Effects of Glucagon-Like Peptide-1 Agonist Therapy (Semaglutide and Tirzepatide) on Metabolic and Hormonal Parameters in Men with Obesity and Insulin Resistance. Global Scientific Review. 48, (Feb. 2026), 42–45.